GlassScriptPhysician profile
Don Howard Steinfeld
NPI 1205863362
$1,765.54
in general payments reported to CMS, 2019-2025
12 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $143 · 2021: $169 · 2022: $147 · 2023: $209 · 2024: $540 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $515.49 | 2021-2025 | Eterna |
| Amgen INC. | $296.53 | 2024-2025 | Krystexxa |
| Cardiovascular Systems INC. | $255.28 | 2020-2022 | |
| Djo, LLC | $199.58 | 2023-2024 | Cmf |
| Horizon Therapeutics Plc | $149.32 | 2021-2023 | Krystexxa |
| Smith+Nephew, INC. | $110.13 | 2019-2021 | |
| Medtronic, INC. | $75.23 | 2025 | Closurefast |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $72.05 | 2019 | |
| Averitas Pharma INC. | $37.48 | 2025 | Qutenza |
| Integra Lifesciences Corporation | $22.28 | 2020 | |
| Mimedx Group, INC. | $17.17 | 2024 | |
| Abbvie INC. | $15.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Don Steinfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.